Trial Profile
Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2020
Price :
$35
*
At a glance
- Drugs Conivaptan (Primary)
- Indications Brain oedema; Cerebral haemorrhage
- Focus Adverse reactions
- 06 Apr 2020 Results assessing the safety and tolerability of conivaptan, a non-peptide vasopressin (AVP) receptor antagonist, for the management of PHE in ICH patients published in the Clinical Drug Investigation
- 30 May 2019 Status changed from recruiting to completed.
- 04 Apr 2017 Status changed from not yet recruiting to recruiting.